Curacyte in shock Phase III failure
This article was originally published in Scrip
Executive Summary
Curacyte has terminated a Phase III trial of its shock treatment PHP/Hemoximer on the recommendation of the data monitoring board. It follows a review of data from 300 patients, or 66% of the study population, which showed that the addition of the drug led to an increased number of deaths compared with the placebo arm. This was the third interim analysis on safety and mortality of the trial.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.